User:Mr. Ibrahem/Insulin glulisine

Insulin glulisine, sold under the brand name Apidra, is a rapid acting insulin used to treat type 1 and type 2 diabetes. It is given by injection under the skin between 15 minutes before to 20 minutes after starting a meal. It may also be used by injection into a vein. It is generally used with a long acting insulin.

Common side effects include low blood sugar and pain at the site of injection. Other side effects may include allergic reactions, low potassium, and lipodystrophy. It is made by recombinant DNA techniques.

Insulin glulisine was approved for medical use in the United States and Europe in 2004. In the United Kingdom 300 units costs the NHS about £6 as of 2021. In the United States this amount costs just over 100 USD.